Yahoo · Sep 28, 2026
Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says
Vaxcyte's (PCVX) upcoming data readout for its investigational pneumococcal conjugate vaccine VAX-31
PC
NASDAQ · PCVX
Vaxcyte, Inc. Common Stock
Healthcare · Biotechnology
$73.82
Down-$7.12 (-9.65%)
Updated Oct 7, 2026, 1:21 AM
SID Score
6.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.84B
- P/E ratio
- -9.24
- Dividend yield
- 0.00%
- 52-week range
- $39.87 – $90.75
- Volume
- 14.92M
- Avg. volume
- 1.73M
Price performance · PCVX
PCVX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
PCVX closed at $73.82 after 20 trading sessions, up 22.30% for the selected period.
- Last close
- $73.82
- Period change
- +22.30%
- Period low
- $56.05
- Period high
- $73.82
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $87.21 | $90.75 | $71.60 | $73.82 | 14.92M |
| Oct 2, 2026 | $56.76 | $57.00 | $55.84 | $56.48 | 2.4M |
| Oct 1, 2026 | $56.73 | $57.17 | $55.995 | $56.05 | 1.17M |
| Sep 30, 2026 | $56.69 | $57.505 | $56.1273 | $56.90 | 1.51M |
| Sep 29, 2026 | $57.96 | $58.9811 | $55.91 | $56.69 | 1.49M |
| Sep 28, 2026 | $56.50 | $58.82 | $55.75 | $58.27 | 1.85M |
| Sep 25, 2026 | $57.22 | $57.496 | $55.92 | $56.21 | 947.29K |
| Sep 24, 2026 | $55.86 | $57.59 | $55.085 | $56.90 | 1.85M |
| Sep 23, 2026 | $59.02 | $59.10 | $55.09 | $56.495 | 1.65M |
| Sep 22, 2026 | $59.45 | $59.96 | $58.78 | $59.02 | 1.28M |
| Sep 21, 2026 | $59.00 | $60.535 | $57.615 | $58.92 | 1.12M |
| Sep 18, 2026 | $60.37 | $60.37 | $57.01 | $58.13 | 2.72M |
| Sep 17, 2026 | $60.22 | $61.50 | $59.31 | $60.37 | 1.31M |
| Sep 16, 2026 | $59.25 | $60.13 | $58.40 | $58.77 | 1.25M |
| Sep 15, 2026 | $59.70 | $59.75 | $58.185 | $59.21 | 1.89M |
| Sep 14, 2026 | $60.04 | $60.8547 | $59.085 | $59.54 | 1.43M |
| Sep 11, 2026 | $60.07 | $60.20 | $58.21 | $59.47 | 1.68M |
| Sep 10, 2026 | $59.19 | $60.13 | $58.555 | $58.90 | 1.16M |
| Sep 9, 2026 | $59.99 | $60.33 | $59.045 | $59.51 | 1.2M |
| Sep 8, 2026 | $60.25 | $61.03 | $59.22 | $60.36 | 1.02M |
Latest PCVX news
The latest Smart Investors Daily articles mentioning PCVX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PCVX research
Overview
Company profile and research snapshot.
Company profile
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $77.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Needham | Buy | — |
| Oct 5, 2026 | BTIG | Buy | — |
| Oct 5, 2026 | Guggenheim | Buy | — |
| Sep 28, 2026 | B of A Securities | Buy | — |
| Sep 25, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 28, 2026
Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.
Benzinga · Sep 28, 2026
B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130
B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.
Benzinga · Sep 25, 2026
Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Target
Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $110 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
